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Abstract
Introduction: Ischemia/reperfusion after cardiopulmonary resuscitation (CPR) induces systemic inflammatory
response and activation of endothelium and coagulation, resulting in a post-cardiac arrest syndrome. We analysed
circulating (annexin V+) microparticles and their conjugates in resuscitated patients.
Methods: 36 patients after successful resuscitation, 20 control patients with stable cardiac disease and 15 healthy
subjects were included prospectively. Two blood samples were drawn, one immediately and one 24 hours after
return of spontaneous circulation (ROSC) to detect (annexin V+) monocyte-derived microparticles (MMPs) or
procoagulant (annexin V+) platelet-derived microparticles (PMPs) and conjugates of endothelial-derived (annexin V
+) microparticles (EMPs) with monocytes (EMP-MC) or platelets (EMP-PC). Measurements were performed by flow
cytometric analysis. Additionally, the effect of isolated microparticles on cultured endothelial cells was assessed by
ELISA.
Results: MMPs were significantly elevated immediately after ROSC compared to the cardiological control group
(control; p < 0.01) and healthy subjects (healthy; p < 0.05) and persisted to be elevated in the following 24 hours
after CPR (p < 0.05 vs. control and healthy, respectively). Procoagulant PMPs increased within the first 24 hours
after ROSC (p < 0.01 vs. control and p < 0.005 vs. healthy). Conjugates of EMP with monocytes and platelets were
both significantly elevated immediately after CPR (EMP-MC: p < 0.05 vs. control and p < 0.05 vs. healthy; EMP-PC: p
< 0.05 vs. control and p < 0.05 vs. healthy), while only EMP-MC showed persisting high levels within 24 hours after
CPR (p < 0.05 vs. control and p < 0.01 vs. healthy). MMP levels of ≥1.0/μL 24 hours after CPR predicted adverse
outcome at 20 days (p < 0.05). Furthermore, isolated microparticles circulating in CPR patients early after ROSC led
to enhanced endothelial apoptosis ex vivo compared to those of the healthy controls (p < 0.005).
Conclusions: Resuscitated patients show substantially increased levels of different (annexin V+) microparticles and
their conjugates immediately and 24 hours after cardiopulmonary resuscitation, suggesting an early onset of
inflammation, an ongoing endothelial activation and a procoagulatory state. Additionally, microparticles of CPR
patients may contribute to endothelial apoptosis. These results point to an involvement of microparticles in the
development of the post-cardiac arrest syndrome.
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Reperfusion following the return of spontaneous circula-
tion (ROSC) after complete whole-body ischemia is an
unnatural pathophysiological state created by successful
cardiopulmonary resuscitation (CPR). Systemic ische-
mia/reperfusion response induces generalised tissue
damage with a release of reactive oxygen species and
endothelial-leukocyte interaction, resulting in a systemic
inflammatory response [1,2], endothelial activation and
injury [3-5], and coagulation abnormalities [6-8]. This
so-called post-cardiac arrest syndrome shares many fea-
tures with severe sepsis and may complicate the clinical
course of resuscitated patients at the ICU [1,9].
Microparticles (MPs) are small vesicles, which typi-
cally range in size from 0.1 to 1.5 μm[ 9 ] ,s h e df r o mt h e
plasma membrane into the extracellular space by most
eukaryotic cells undergoing activation or apoptosis.
They result from translocation of phosphatidylserine
from the inner to the outer leaflet of the cell membrane
where they express antigens characteristic of their cell
of origin [10]. MPs are considered to act as diffusible
messengers [11], to transport bioactive agents, and to
initiate and mediate coagulation [12], inflammation and
cell-cell interactions [13].
Monocyte-derived microparticles (MMPs) contain
organized membrane receptors including ß2-integrins,
like Mac-1 (CD11b/CD18). Therefore, they are capable
of binding endothelial cells [11] and acting as competent
inflammatory agonists by stimulation of cytokine release
and up-regulation of endothelial adhesion molecules
[14]. Additionally, MMPs play a crucial role in the
initiation of endothelial dysfunction, endothelial throm-
bogenicity and apoptosis [14-16] and are capable of
e x p o s i n gah i g h l yc o a g u l a n ttissue factor [17]. Accord-
ingly, elevated numbers of MMPs have so far been
reported in patients with multiorgan failure, who devel-
oped severe disseminated intravascular coagulation
[17,18], and in acute coronary syndromes, including
acute myocardial infarction [19,20], underlining their
inflammatory and procoagulant potential.
The second group, the platelet-derived microparticles
(PMPs) are released by activated platelets [21] and are
able to activate platelets and endothelial cells [22],
monocyte adhesion [23] and the release of inflammatory
cytokines [24] and induce endothelial apoptosis [25].
Consequently, elevated numbers of PMPs have been
found in patients suffering from diseases associated with
an increased risk of thromboembolic processes and vas-
cular damage, including acute coronary syndromes [26],
ischemic cerebrovascular disease [27] and peripheral
arterial disease [28].
Endothelial-derived microparticles (EMPs) have been
shown to be elevated after cardiopulmonary resuscita-
tion [5] and in various states of disturbed endothelial
function. EMPs have been shown to interact with mono-
cytes or platelets to form circulating conjugates [29,30].
EMP-monocyte conjugates have been shown to be sensi-
tive markers of disease activity in many disorders,
including inflammatory and procoagulant conditions
such as severe sepsis [31], multiple sclerosis [32], sys-
temic lupus erythematosus, antiphospholipid syndrome
[33] and venous thromboembolism [34]. An enumera-
tion of EMP-platelet conjugates has been considered as
a marker of activation of coagulation and endothelial
cells as well as endothelial damage [30]. High numbers
of these conjugates have been detected in the peripheral
blood of patients with stable coronary disease [30].
Intention of the study
In the present study, we aimed to investigate the effect
of whole-body ischemia/reperfusion after successful CPR
on the occurrence of different MPs and their conjugates
in peripheral blood of resuscitated patients and their
influence on patients’ survival. Additionally the effect of
MPs of resuscitated patients on endothelial cells was
evaluated. As these MPs indicate and maintain inflam-
matory, coagulation and endothelial injuring processes,
they are possible players in the field of post-cardiac
arrest syndrome and may be indicators to predict out-
come or possible targets of future therapeutic
interventions.
Materials and methods
Study subjects
Patient recruitment
After the institutional approval of the Ethics Committee
of our institution (EK-Freiburg 328/09), we included 36
patients who underwent CPR after cardiac arrest to
measure PMPs and MMPs, EMP-monocyte and EMP-
platelet conjugates. All patients were treated according
to the international guidelines given by International
Liaison Committee on Resuscitation in 2008 [35] and
therefore received all therapeutic hypothermia. Results
were compared with 20 patients with stable cardiac dis-
ease on a cardiological ward. As a second control, we
performed measurements in 15 healthy subjects taking
no medication and carrying no cardiovascular risk.
Inclusion and exclusion criteria
Inclusion criteria were CPR following cardiac arrest of
any cause, in- or out-of-hospital with duration of CPR
five minutes or longer. Resuscitation was performed
according to the European Resuscitation Council Guide-
lines for Resuscitation 2005 [36-38]. Patients with malig-
nant diseases were excluded from the study, because
elevation of MPS has been reported to be increased in
various malignancies [39]. Similarly, patients younger
than 18 years, patients with sepsis or severe inflamma-
tion or trauma patients were excluded. Informed
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with good neurological outcome or from their relatives
in case of the non-surviving. Informed consent was
given by all patients in the control groups.
Baseline characteristics
In resuscitated patients, data concerning the resuscita-
tion period, for example, duration and location of CPR,
time from cardiac arrest to start of mechanical resusci-
tation (no-flow time), presenting rhythm and presum-
able cause for cardiac arrest, were recorded. Baseline
characteristics, such as age, gender, co-morbidities, car-
diovascular risk profile, therapy received (medication, or
coronary angiography), and some selected values of the
local laboratory were collected. Additionally outcome
parameters such as survival until hospital discharge,
consecutive organ failure (definitions: acute kidney fail-
ure = increase in creatinine ≥0.3 mg/dL, or ≥1.5-fold
climb in baseline creatinine within 48 hours; acute liver
failure = increase in International Normalized Ratio ≥0.5
within 72 hours; acute heart failure = clinical signs of
cardiac decompensation or cardiogenic shock), severity
of disease (with the help of Sequential Organ Failure
Assessment (SOFA)) and neurological outcome (on the
basis of Glasgow Outcome Scale (GOS)) of survivors
were recorded in both groups (Table 1).
Laboratory methods
Blood sampling and handling
Blood samples in resuscitated patients were collected
immediately after admission to the ICU and 24 hours
after ROSC, using an arterial line. In controls and
healthy subjects, 20 mL blood was drawn from the
arterial line in case of coronary catherization or by veni-
puncture on the second day and in healthy controls,
respectively. Samples were drawn slowly, handled care-
fully and analysed immediately after sampling. For veni-
puncture, we used a 21-gauge butterfly needle and
discarded the first 7.5 mL.
Antibodies
The following monoclonal antibodies (mAb) were pur-
chased from Beckman Coulter (Marseille, France): anti-
human CD61-FITC, anti-human CD14-FITC. Anti-
human CD11b-FITC was purchased from Becton Dick-
i n s o n( S a nJ o s e ,C A ,U S A ) ,a n n e x i nVa n dt h em o u s e
IgG1-PE and IgG1-FITC were from BD Biosciences
Pharmingen (San Diego, CA, USA) and anti-CD62E-PE
was obtained from Southern Biotech (Birmingham, AL,
USA).
Flow cytometry analysis
Flow cytometry was performed using a three-colour
FACSCalibur™ cytometer (BD Biosciences; San Jose,
CA, USA) running Cell-Quest™ version 3.3 (BD Bios-
ciences, San Jose, CA, USA), acquisition and analysis
software. Instrument setup with individual settings for
each antibody and calibration were performed with Cali-
BRITE™ beads (BD Biosciences, San Jose, CA, USA),
according to the manufacturer’s recommendations.
Sample preparation for measurement of MMPs,
procoagulant PMPs, and EMP-platelet conjugates
Blood samples were collected in citrated tubes. Accord-
ing to the protocol of Hughes et al., samples were cen-
trifuged for 10 minutes at 240 g at room temperature to
obtain platelet-rich plasma and MPs were distinguished
from platelets on the basis of their characteristic flow
cytometric profile [40]. Supernatant was diluted 1:50
with Tyrode buffer and was incubated for 30 minutes at
room temperature in the dark with fluorochrome-
labelled antibodies. After the fixation of the tubes with
300 μL of CellFix™ (BD Biosciences, Erembodegem-
Aalst, Belgium), samples were ready to be analysed by
flow cytometry. MPs were counted on the basis of the
events, positive for the cell-specific mAbs (see below)
and values are given in counts/μL. Counts were calcu-
lated as events/36, because samples were analysed at a
flow rate of 12 μL/min for 180 seconds (according to 36
μL/180 sec.).
Sample preparation for measurement of EMP-monocyte
conjugates
For monocyte preparation, whole blood (100 μL) col-
lected in citrated tubes was incubated with 2 mL FACS
Lysing Solution™ ( B DB i o s c i e n c e s ,S a nJ o s e ,C A ,U S A )
at room temperature for 10 minutes. After centrifuga-
tion at 1,000 rpm for five minutes, supernatant was dis-
carded, pellet washed twice with 2 mL PBS and
resuspended in 50 μL PBS. Samples were incubated in
the dark with anti-CD14-FITC and anti-CD62E. Mouse
IgG1-PE or IgG1-FITC served as negative control. Fol-
lowing incubation, the samples were fixed with Cell-
Fix™ (BD Biosciences, Erembodegem-Aalst, Belgium)
prior to analysis. Samples were analysed at a flow rate of
36 μL/min until 10,000 monocytes were collected in a
specific monocyte gate. Values are given in counts/100
monocytes.
Identification of MMPs and procoagulant PMPs
As CD11b is a subunit of Mac-1, representing an acti-
vated state of the monocytic MP subset, we chose anti-
human CD11b-FITC for detection of MMPs. Procoagu-
lant PMPs were identified by anti-human CD61-FITC, a
beta-3-integrin on platelets. Mouse IgG1-PE or IgG1-
FITC served as the negative control. During incubation,
the cytometer was rinsed with FacsFlow™ (BD Bios-
ciences, Erembodegem-Aalst, Belgium) for at least 30
minutes. MPs were gated by a size of less than 1 μmb y
using beads (Megamix™, Biocytex, Marseille, France)
with a defined size of 0.9 μm (Figure 1). To check on
the assumed identity as phosphatidylserine-expressing
circulating MPs annexin V labelling was performed in
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Page 3 of 13Table 1 Baseline characteristics of resuscitated and control patients
CPR Control P value
n =3 6 n =2 0
%%
Age (years) 63.9 ± 2.1 65.7 ± 2.5 0.58/ns
Gender Male 28 78 16 80 0.85/ns
Female 8 22 4 20
Cause of CA or Cardiac 23 64 20 100 <0.005
hospital admission Non-cardiac 10 28 0 0
Unknown 3 8 0 0
Coronary angiography 23 64 12 60 0.78/ns
Location of CPR out-of-hospital 27 75
in-hospital 9 25
Duration of CPR (min) 21.8 ± 2.5
No-flow time (min) 4.5 ± 0.8
Initial rhythm VT/VF 20 56
Asystole/PEA 16 44
Outcome Survival to discharge 14 39 20 100
GOS (survivors) at discharge 4.4 ± 0.2 5.0 ± 0.0
SOFA score day 1 11.0 ± 0.4
SOFA score day 2 10.6 ± 0.4
Medication at ICU Vasopressors 20 56 0 0 <0.001
Thrombolysis 3 8 0 0 0.18/ns
GPIIb/IIIa blockers 16 44 2 10 < 0.001
Acetylsalicylic acid 25 69 15 75 0.66/ns
Clopidogrel 21 58 12 60 0.90/ns
Medication prior to event Statins 8 22 12 60 <0.01
Consecutive organ Acute renal failure 8 22 0 0 <0.05
failure Acute liver failure 3 8 0 0 0.54/ns
Acute heart failure 4 11 0 0 0.29/ns
Co-morbidities CAD 24 67 14 70 0.80/ns
PAD 4 11 5 25 0.26/ns
Chronic heart failure 2631 5 0.34/ns
Chronic renal insufficiency 4 11 2 10 0.99/ns
Liver insufficiency 4 11 0 0 0.29/ns
Pulmonary disease 9 25 6 30 0.69/ns
Cardiovascular risk Hypertension 16 44 15 75 <0.05
factors Hyperlipidemia 6 17 11 55 <0.005
Diabetes 9 25 2 10 0.29/ns
Smoking 7 19 8 40 0.10/ns
Laboratory values Leukocytes/μL (day 1) 15.5 ± 1.1 7.7 ± 0.5 <0.001
Leukocytes/μL (day 2) 13.7 ± 1.5 7.7 ± 1.0 <0.005
Platelets/μL (day 1) 203.7 ± 12.3 231.9 ± 12.9 0.12/ns
Platelets/μL (day 2) 183.9 ± 12.4 200.9 ± 41.0 0.7/ns
CRP mg/L (day 1) 37.2 ± 11.3 8.7 ± 2.9 <0.05
CRP mg/L (day 2) 56.8 ± 12.1 6.3 ± 1.4 <0.001
Basic data of the cardiopulmonary resuscitation and the cardiological control group (Control). Both groups are comparable in baseline variables including age,
gender, incidence of coronary artery disease, coronary angiography, congestive heart failure and other relevant secondary disorders. There are slight but
significant differences in distribution of cardiovascular risk factors as well as co-medication.
CA, cardiac arrest; CAD, coronary artery disease; CPR, cardiopulmonary resuscitation; CRP, C-reactive protein; GOS, Glasgow Outcome Scale; ns, statistically not
significant; PAD, peripheral artery disease; PEA, pulseless electrical activity; SOFA, Sequential Organ Failure Assessment; VF, ventricular fibrillation; VT, ventricular
tachycardia.
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ing on the fluorescence signal above background noise.
Identification of EMP-monocyte and EMP-platelet
conjugates
EMPs were identified by the activation-specific surface
marker E-selectin (CD62E). Conjugates of EMPs with
other cells were detected by employing strategic combi-
nations of fluorescent-labelled antibodies depending on
co-expression of endothelial marker CD62E with mono-
cytes or platelets and expected bit-map location. Mono-
cytes were identified and gated by positive staining for
CD14, platelets by staining for CD61.
Measurement of IL-6 in resuscitated patients
In resuscitated patients, analysis was accompanied by
the measurement of plasma IL-6 levels by chemilumi-
nescent immunoassay in the central laboratory of the
university hospital, Freiburg. Levels were compared with
normal values of our institutional laboratory (<15 pg/
mL).
Isolation of circulating MPs from resuscitated patients and
healthy volunteers
MP isolation from citrated blood samples was performed
according to the protocol of Boulanger et al. [41]. In brief
platelet-free plasma was obtained by centrifugation at
11,000 g for two minutes and was subjected to further
centrifugation at 13,000 g for 45 minutes. The MP pellets
were resuspended in 100 μL of RPMI medium (contain-
ing Hepes and L-glutamine, from Lonza, Verviers, Bel-
gium) and stored at -80°C until further analysis.
Supernatant, containing the corresponding plasma of
subjects were also kept and stored at -80°C to serve as
the negative control. MP protein content was assessed by
Bio-Rad Protein Assay (Bio-Rad Laboratories GmbH,
München, Germany) and adjusted to the same values for
each subgroup in the experiments.
Endothelial cell culture
Human umbilical vein endothelial cells (HUVEC) were
obtained from Promocell™ (Heidelberg, Germany). The
cells were cultured. For incubation with MPs, 10
4 cells
per well were cultured in endothelial cell growth med-
ium advanced (Provitro, Berlin, Germany) at 37°C in a
5% CO2 humidified atmosphere overnight. The follow-
ing day cells were subjected to Optimem medium
(Gibco, Invitrogen, Karlsruhe, Germany) and incubated
with isolated MPs from resuscitated patients, healthy
subjects or their corresponding plasma. MPs were added
to equal protein content per well and incubated with
HUVECs for 24 hours.
Ex vivo detection of apoptosis in cultured endothelial cells
by ELISA
Detection and quantification of apoptosis in HUVECs
after incubation with MPs or plasma of resuscitated and
healthy probands was performed by the Cell Death
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Figure 1 Flow cytometric detection of microparticles in
peripheral blood. Three-colour flow cytometry evaluation of
microparticles. (a) Detection of particles with a size of less than 1
μm by nano-beads, (b) then gating of microparticles in the lower
left. (c) Events staining positive for the fluorochrome-labelled
antibody directed against CD14 were identified as monocyte-
derived microparticles (MMPs).
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Page 5 of 13Detection ELISA™ (Boehringer, Mannheim, Germany),
according to the manufacturer’s instructions. This is a
colorimetric one-step sandwich ELISA for relative quan-
tification of apoptosis by detection of histone-complexed
DNA fragments (mono- and oligonucleosomes) after cell
lysis.
Statistical analysis
Continuous variables are given as means ± standard
error of the mean. Data of CPR, control patients and
h e a l t h yw e r ec o m p a r e db yM a n n - W h i t n e yU -t e s t ,a s
appropriate. Comparisons between the different study
populations and time points were performed using one-
way repeated-measures analysis of variance, including an
all-pair wise comparison. Correlations between selected
variables were estimated by Spearman’sr a n kc o r r e l a t i o n
coefficient. Basic data and outcome were compared by
Fisher’s exact test, Chi-square test, and Student’st - t e s t ,
respectively. Statistical significance was defined as a
two-tailed P < 0.05. Analyses were performed with SPSS
version 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of patients
In the group of resuscitated patients, mean duration of
mechanical resuscitation was 21.8 ± 2.5 minutes and esti-
mated no-flow time was 4.5 ± 0.8 minutes. The presenting
rhythm was ventricular fibrillation or ventricular tachycar-
dia in 56% versus asystole or pulseless electrical activity in
44%. Twenty three patients (64%) presented a presumable
cardiac cause for cardiac arrest and 14 patients (39%) sur-
vived until hospital discharge and mean GOS of survivors
was 4.4 ± 0.2 at discharge. Severity of disease was
evaluated by SOFA [42]. Mean SOFA score immediately
a f t e rC P Rw a s1 1 . 0±0 . 4a n d1 0 . 6±0 . 42 4h o u r sl a t e r
(Table 1). Average time from ROSC to first blood sam-
pling was three hours and 42 minutes ± 48 minutes. The
second blood sample was collected 25 hours and 48 min-
utes ± 42 minutes after ROSC.
Patients of the resuscitation and cardiological control
group were comparable in baseline characteristics such
as gender and age, as well as presence of a significant
coronary artery disease (CAD) in medical history and
proportion of subjects, which underwent coronary
angiography during the blood sampling period of about
26 hours (Table 1). There were slight differences in car-
diovascular risk profiles between the two groups with a
higher incidence of hyperlipidemia in the control group.
Resuscitated patients showed elevated leukocyte count
and C-reactive protein levels but comparable platelet
count compared with controls. Patients in the CPR
group presented significantly higher incidence of acute
renal failure, compared with control patients (Table 1).
All measurements were also performed in 15 healthy
controls. Age at time of the study was 31.3 ± 1.9 years.
MMPs and procoagulant PMPs
The mean number of MMPs in CPR patients was signif-
icantly increased immediately after ROSC compared
with controls being hospitalized for a cardiac cause
(mean number 2.2 ± 0.4 vs. 0.3 ± 0.06 events/μL; P <
0.01) or healthy controls (mean number 0.5 ± 0.1
events/μL; P < 0.05) and persisted in the 24 hours follow
up (mean number vs. control: 2.2 ± 0.8 vs. 0.5 ± 0.2
events/μL; P < 0.05; or vs. healthy: 0.5 ± 0.2 events/μL;
P < 0.05; Figure 2). In all groups, there was no
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Figure 2 Elevated monocyte-derived microparticles in patients after CPR. Significant elevation of monocyte-derived microparticles (MMPs)
in peripheral blood of resuscitated patients (cardiopulmonary resuscitation (CPR); black bars) immediately (left) and 24 hours after return of
spontaneous circulation (right) compared with control patients with cardiac cause of hospital admission (Control; grey bars) and healthy subjects
(Healthy; white bars). (* P < 0.01;
# P < 0.05 versus CPR).
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up (CPR: P =0 . 2 2 ;c o n t r o l :P = 0.85; healthy: P = 0.48)
and there was no correlation between monocyte count
and MMP count detectable (r
2 = 0.01; P = 0.78).
Similarly procoagulant PMP levels were elevated in
resuscitated patients. Whereas the mean number (35.1 ±
16.2 events/μL) was only significantly elevated compared
with healthy subjects immediately after CPR (mean
number 6.2 ± 2.9 events/μL; P < 0.05), there was only a
slight but not significant increase detectable compared
with the cardiological control group (mean number 22.8
± 11.2 events/μL; P = 0.33). Twenty four hours after
ROSC the mean number of procoagulant PMPs (67.9 ±
25.6 events/μL) in resuscitated patients was significantly
higher than in the cardiological control group (mean
number 11.3 ± 1.7 events/μL; P < 0.01) and in healthy
subjects (mean number 6.4 ± 2.0 events/μL; P < 0.005;
Figure 3). Increase in procoagulant PMP count in the
first 24 hours in resuscitated patients failed to reach sig-
nificance (P = 0.11) and there was also no significant
difference between number of procoagulant PMPs in a
follow up of 24 hours in both control groups (control: P
= 0.74; healthy: P = 0.37). There was no correlation
between platelet count and number of procoagulant
PMP in all groups (r
2 = 0.02; P = 0.47).
EMP-monocyte and EMP-platelet conjugates
In resuscitated patients, significantly raised levels of
EMP-monocytes conjugates were detectable compared
with control patients and healthy controls immediately
after ROSC (control: 2.9 ± 0.9 vs. 1.0 ± 0.2 events/100
monocytes; P < 0.05; healthy: 1.0 ± 0.2 events/100
monocytes; P < 0.05) and 24 hours after CPR (control:
3.0 ± 0.8 vs. 1.4 ± 0.5 events/100 monocytes; P < 0.05;
healthy: vs. 0.6 ± 0.2 events/100 monocytes; P <0 . 0 1 ;
Figure 4). There was no significant difference in count
of EMP-monocytes conjugates immediately after ROSC
compared with the 24 hours follow up (CPR: P = 0.66;
control: P = 0.95; healthy: P = 0.26) in all groups. There
was no correlation between monocyte count and num-
ber of EMP-monocyte conjugates (r
2 = 0.07; P = 0.70).
Number of EMP-platelet conjugates was significantly
elevated immediately after ROSC (91.0 ± 17.7 events/μL)
compared with patients in the cardiological control group
(43.4 ± 7.8 events/μL; P < 0.05) and healthy controls (29.6
±8 . 0e v e n t s / μL; P < 0.05; Figure 5). Twenty four hours
later, there was no more difference to the control group of
patients being hospitalized for a cardiac cause (66.3 ± 17.3
events/μL vs. 65.8 ± 9.4 events/μL; P = 0.98), but an eleva-
tion compared with healthy subjects (26.2 ± 7.5 events/μL;
P < 0.05) persisted. Decrease in numbers of EMP-platelet
conjugates in the first 24 hours in resuscitated patients did
not reach significance (P = 0.22) and there was also no sig-
nificant difference between numbers of EMP-platelet con-
jugates in the control groups in a follow up of 24 hours
(control: P = 0.06; healthy: P = 0.93). Comparable with
EMP-monocyte conjugates, there was no correlation
between platelet count and the number of EMP-platelet
conjugates (r
2 =0 . 0 1 ;P = 0.58).
Prognostic value of circulating (annexin V+) MPs
To evaluate the prognostic value of different levels of
(annexin V+) MPs, we compared the 20-day survival of
groups divided by a certain cut-off value of the different
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Figure 3 Elevated procoagulant platelet-derived microparticles in patients after CPR. Elevated number of procoagulant platelet-derived
microparticles (PMPs) in resuscitated patients (cardiopulmonary resuscitation (CPR); black bars) compared with healthy controls (Healthy; white
bars) immediately (left) and 24 hours after return of spontaneous circulation (right). Compared with control patients with cardiac cause of
hospital admission (Control; grey bars), procoagulant PMP count was only slightly higher immediately after CPR (left), coming up to a significant
elevation 24 hours later (right). (
## P < 0.005; * P < 0.01;
# P < 0.05; ns, statistically not significant versus CPR).
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after ROSC.
In the MMP group, 50% of the patients with less than
1.0 MMPs/μL immediately after ROSC survived more
than 20 days after CPR versus 36% of those with MMPs
1.0 MMPs/μL or more (P = 0.59), while 67% versus 14%
survived longer than 20 days, when the MMP level was
less than 1.0 MMPs/μL on the second day after CPR
(vs. ≥1.0 μL; P < 0.05; Figure 6).
Patients with procoagulant PMPs less than 10.0 PMPs/
μL immediately after ROSC survived more than 20 days
in 57 vs. 29% (P = 0.13) and in 56 vs. 27% (P =0 . 2 0 ) ,
when level of procoagulant PMP was 10.0/PMPs/μLo r
morein the 24 hour follow up (Figure 7).
There were no differences concerning the EMP conju-
gates with monocytes or platelets immediately after
ROSC (42 vs. 43% for < or ≥ 5 EMP-monocyte conju-
gates/100 monocytes, respectively; P =0 . 9 6a n d4 1v s .
40% < or ≥ 50 EMP-platelet conjugates/μL, respectively;
P = 0.95). Twenty four hours later, there was still no
significant difference between patients presenting with
less than five and five or more EMP-monocyte
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Page 8 of 13conjugates/100 monocytes (50 vs. 40%; P = 0.67) or
between subjects with less than 50 related to those with
50 or more EMP-platelet conjugates/μL (31 vs. 50%; P =
0.38).
IL-6 levels in resuscitated patients
Resuscitated patients showed significantly elevated
plasma levels of IL-6 immediately (430.5 ± 148.6 pg/mL;
P < 0.05) and 24 hours after ROSC (1067.5 ± 185 pg/
mL; P < 0.01) compared with normal values of our insti-
tutional laboratory (<15 pg/mL).
MP-induced apoptosis in HUVECs
Endothelial cells viability was evaluated ex vivo by a
DNA fragmentation ELISA after incubation with MPs
or plasma obtained from resuscitated patients and
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Page 9 of 13healthy subjects. MPs of resuscitated patients isolated
immediately after CPR resulted in significantly enhanced
endothelial apoptosis compared with plasma of CPR
patients (1.7 ± 0.3 vs. 0.4 ± 0.05 RFU; P <0 . 0 0 5 ) ,a s
well as compared with purified MPs of healthy controls
(1.7 ± 0.3 vs. 0.5 ± 0.04 RFU; P < 0.005). This elevated
apoptosis rate was notable only in trend for MPs iso-
lated 24 hours after ROSC, but there were no more sta-
tistically significant differences, neither in comparison to
plasma (1.2 ± 0.5 vs. 0.4 ± 0.04 RFU; P = 0.11) nor to
isolated microparticles of healthy (1.2 ± 0.5 vs. 0.5 ±
0.04 RFU; P = 0.15; Figure 8).
Discussion
Our study demonstrates that different subtypes of
(annexin V+) MPs and their conjugates are elevated and
may influence the clinical course of patients after suc-
cessful CPR. The main findings were a marked elevation
of MMPs and EMP-monocyte conjugates immediately
and in the following 24 hours after ROSC compared
with control patients hospitalized for cardiac causes and
healthy subjects. Additionally, we found increasing levels
of procoagulant PMPs in the 24 hour follow up after
CPR and a significant increase of EMP-platelet conju-
gates early after ROSC compared with both control
groups. These results suggest an early onset of inflam-
mation, an ongoing process of endothelial activation and
a procoagulatory state and thereby, an involvement of
(annexin V+) MPs in the development of the post-car-
diac arrest syndrome. Additionally, we found MMP
levels of 1.0 MMPs/μL or more on the second day after
ROSC to be a prognostic value to predict outcome at 20
days after cardiac arrest.
As MPs are known to be elevated in CAD patients
[20,30], we compared resuscitated subjects with patients
with stable cardiac disease, mostly presenting CAD and
undergoing coronary catherization in a similar propor-
tion, to exclude possible effects caused by CAD or cor-
onary intervention in the resuscitation group.
Additionally, we included a smaller population of
healthy volunteers.
The most impressive finding of the study is the strong
elevation of MMPs and EMP-monocyte conjugates after
CPR. The considerable increase immediately after ROSC
was followed by persistently high levels in the first 24
hours after ROSC. Formation of leukocyte-derived MPs
in general is enhanced by inflammatory stimuli and
MMPs are known to be important in vivo markers of
neutrophil activation [43]. They are capable of expres-
sion of selectins and integrins, which makes them candi-
dates for playing a crucial role in inflammation and cell
signalling [44], suggesting a distinct inflammatory pro-
cess occurring in patients after CPR. Additionally,
MMPs are competent inflammatory mediators to induce
endothelial activation and cytokine production [14], thus
potentially contributing to endothelial activation and
dysregulation [5,15,45]. On the other hand, EMPs, shed
by the activated endothelium, have been shown to be
elevated after CPR [5] and are known to bind to mono-
cytes in a time- and concentration-dependant manner
[29] to form EMP-monocyte conjugates. Once bound to
monocytes, they activate them to enhanced expression
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Page 10 of 13of integrins and migration through the endothelial cell
layer [29,32]. Our results are in line with various reports
of an inflammatory in patients after CPR [1-4]. Accord-
ingly, IL-6 levels were also significantly elevated in
resuscitated patients at both time points, whereas the
preserved elevation of MMPs and EMP-monocyte con-
jugates in our study provides evidence for an ongoing
inflammatory state in the first 24 hours of reperfusion.
This is also reflected by a persistent elevation of inflam-
matory markers such as leukocyte count and C-reactive
protein immediately and 24 hours after CPR compared
with control patients. We could not observe any correla-
tion between monocyte count and number of MMPs, or
EMP-monocyte conjugates so that the results give the
impression that (annexin V+) MP and conjugate counts
are independent markers of inflammation and not only
elevated arising from a general elevation of leukocytes
or monocytes in resuscitated patients.
Other players in this field of activated coagulation and
leukocyte/endothelial interaction are PMPs. As the
phospholipid-dependent procoagulant activity of PMPs
is limited to the annexin V positive subpopulation [46],
we measured procoagulant PMPs in this study, which
were also elevated after CPR. PMPs in general are
formed by the attachment of platelets to the vascular
wall. Besides their procoagulant properties they are able
to directly activate platelets [22]. Furthermore, they are
able to increase the adherence of monocytes to endothe-
lial cells by the up-regulation of adhesion molecules
[ 2 3 ] .T h e r e f o r e ,J ye ta l .s u g g e s t e dap o s s i b l er o l eo f
PMPs as an activator of neutrophils in ischemic injury,
thrombosis and inflammation [47]. Our data match stu-
dies which revealed an increase of procoagulant PMPs
in patients with ischemia/reperfusion, vascular injury
and a risk of thromboembolism such as acute coronary
syndromes [20,26] or ischemic stroke [27]. As levels of
procoagulant PMP were elevated compared with con-
trols presenting CAD in a similar proportion to the
resuscitated, we can exclude the possibility that CAD
alone contributed to this effect.
Procoagulant PMPs were significantly elevated imme-
diately after CPR compared with healthy subjects, but
failed to show a significant difference with respect to
the cardiac patients. This could be due to application of
GPIIb/IIIa receptor antagonists during coronary inter-
vention in a substantial amount of patients (42 vs. 10%
in controls) [20]. In point of fact, the subgroup of
patients receiving GPIIb/IIIa receptor antagonists had a
trend towards lower counts of procoagulant PMP, but
there was no statistical difference between the two sub-
groups (data not shown). Another possible explanation
is given by Nomura et al., who could not detect elevated
levels of free PMPs in patients with multiple sclerosis
and supposed that this was due to an absorbance of
most of the free PMPs to leukocytes, contributing to the
increased platelet-leukocyte conjugates in their study
[24]. Finally, high shear stress can initiate both platelet
aggregation and shedding of procoagulant-containing
MPs [48] and the observed elevation could therefore
also possibly be due to shear stress occurring during
mechanical resuscitation.
Finally, our study revealed higher EMP-platelet conju-
gates immediately after CPR. These conjugates originate
from binding of EMPs to activated platelets and have so
far only been described by Héloire et al. in patients with
CAD. The authors hypothesise that these conjugates ori-
ginate from strongly activated and damaged endothelial
cells and activated platelets and are able to contribute to
thrombus formation by undergoing sequestration in per-
ipheral vessels [30]. In synopsis with our previous find-
ings of a severe endothelial damage early after
resuscitation [5], the elevation of EMP-platelet conju-
gates in resuscitated patients could reflect endothelial
injury and microcirculatory disorders occurring after
CPR.
Interestingly, patients presenting with less than 1.0
MMP/μL on the second day after CPR showed a better
20-day survival after CPR compared with those with 1.0
or more MMPs/μL. Accordingly, we found this in trend
too for patients with less than 10.0 procoagulant PMPs/
μL immediately and 24 hours after CPR, although there
was no statistical significant difference. Therefore, we
suggest a potential prognostic value of MMP counts on
the second day after CPR. It seems likely that the small
number of subjects in each subgroup is due to the fact
that these notable differences did not reach statistically
significant differences.
Additionally, we provide evidence for enhanced apop-
tosis of endothelial cells under the influence of MPs of
resuscitated patients ex vivo.T h i si si nl i n ew i t ho t h e r
publications reporting of endothelial apoptosis under
the influence of different MP subpopulations, such as in
vitro generated MMPs [16] or EMPs [49]. Additionally
Gambim et al. showed that endothelial cells exposed to
PMPs isolated from patients with septic shock undergo
apoptosis [25]. In comparing the effect of MPs with the
effect of plasma of the same patients, we can exclude an
apoptotic effect of certain plasma compounds occurring
after CPR. As we tested the whole amount of circulating
MPs in CPR patients we cannot identify a certain sub-
population contributing to or even initiating apoptosis
in our study.
A limitation of the study could be the sample size,
which is relatively small (n = 36) with a considerable
heterogeneity of the patients, particularly in the CPR
group. Although statistical analysis reveals clear differ-
ences between the groups, these results should be vali-
dated in a larger study.
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With this study, we can demonstrate that different
(annexin V+) MPs and their conjugates are elevated in
patients suffering from cardiac arrest and CPR and
might reflect pathophysiological processes, including
inflammation, activation of coagulation and endothelial
injury, following whole-body ischemia/reperfusion. We
provide evidence for induction of endothelial apoptosis
by MPs circulating in patients after CPR and we can
show a prognostic value in predicting 20-day survival
after resuscitation by MMP levels on the second day
after CPR. Therefore, we suggest an involvement of
MPs in the development of the post-cardiac arrest
syndrome.
Key messages
￿ Patients after successful CPR show a significant
activation of inflammation.
￿ Platelet activation seems to occur 24 hours after
CPR.
￿ Elevated conjugates of EMPs with monocytes or
platelets point to endothelial and platelet activation
and activation of inflammation.
￿ MPs of resuscitated patients induce endothelial
apoptosis.
￿ MMP levels 24 hours after ROSC seem to have
prognostic value.
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